Literature DB >> 21094913

The challenges of cost-effectiveness analyses for the clinician.

Kevin F Erickson, Wolfgang C Winkelmayer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21094913      PMCID： PMC4142430          DOI： 10.1053/j.ajkd.2010.10.001

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


× No keyword cloud information.
  5 in total

Review 1.  The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine.

Authors:  L B Russell; M R Gold; J E Siegel; N Daniels; M C Weinstein
Journal:  JAMA       Date:  1996-10-09       Impact factor: 56.272

2.  Users' guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. A. Are the results of the study valid? Evidence-Based Medicine Working Group.

Authors:  M F Drummond; W S Richardson; B J O'Brien; M Levine; D Heyland
Journal:  JAMA       Date:  1997-05-21       Impact factor: 56.272

3.  An economic evaluation of erythropoiesis-stimulating agents in CKD.

Authors:  Fiona M Clement; Scott Klarenbach; Marcello Tonelli; Natasha Wiebe; Brenda Hemmelgarn; Braden J Manns
Journal:  Am J Kidney Dis       Date:  2010-10-08       Impact factor: 8.860

4.  Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients.

Authors:  Theresa I Shireman; Ammar Almehmi; James B Wetmore; John Lu; Mark Pregenzer; L Darryl Quarles
Journal:  Am J Kidney Dis       Date:  2010-10-15       Impact factor: 8.860

5.  Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.

Authors:  Steven Fishbane; Warren B Shapiro; Dalila B Corry; Steven L Vicks; Michael Roppolo; Kenneth Rappaport; Xiang Ling; William G Goodman; Stewart Turner; Chaim Charytan
Journal:  Clin J Am Soc Nephrol       Date:  2008-11       Impact factor: 8.237
  5 in total
  1 in total

1.  Estimating the optimal individualized treatment rule from a cost-effectiveness perspective.

Authors:  Yizhe Xu; Tom H Greene; Adam P Bress; Brian C Sauer; Brandon K Bellows; Yue Zhang; William S Weintraub; Andrew E Moran; Jincheng Shen
Journal:  Biometrics       Date:  2020-12-09       Impact factor: 2.571
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.